Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

229
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
229
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.2K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Special approach of droplet digital polymerase chain reaction (ddPCR) for transgene stability of a Chinese hamster ovary (CHO) cell line.

BioTechniques·2026
Same author

Aggregating and analysing clinical trials data from multiple public registers using R package ctrdata.

Research synthesis methods·2026
Same author

Dual-drug releasing PEG-PLA hydrogels with tunable degradation for sustained local analgesia and anti-inflammatory therapy in a rat fracture/osteotomy model.

Biomaterials·2026
Same author

Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action.

Nature reviews. Drug discovery·2025
Same author

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025
Same author

Advancing Understanding of Ligneous Conjunctivitis: Bridging Pathogenesis, Diagnosis, and Therapy.

Cornea·2025
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
Same journal

Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

Clinical pharmacology and therapeutics·2026
Same journal

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

Clinical pharmacology and therapeutics·2026
Same journal

Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries.

Clinical pharmacology and therapeutics·2026
Same journal

Quantitative Systems Toxicology Model Predicts Obeticholic Acid-Associated Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical pharmacology and therapeutics·2026
Same journal

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

A Fast Path from Innovation to Safe and Effective Medicines.

Peter Arlett1, Falk Ehmann1, Ralf Herold1

  • 1European Medicines Agency, Amsterdam, The Netherlands.

Clinical Pharmacology and Therapeutics
|October 28, 2025
PubMed
Summary
This summary is machine-generated.

This paper outlines a vision for faster drug development, emphasizing collaboration between regulators, industry, and patients. The goal is to ensure scientific advancements become accessible new medicines for unmet medical needs.

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.6K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.7K

Related Experiment Videos

Last Updated: Jan 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.6K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.7K

Area of Science:

  • Regulatory Science
  • Medicines Development
  • Pharmacological Innovation

Background:

  • Despite progress, unmet medical needs persist, especially in rare diseases, pediatrics, and underserved populations.
  • Pharmacological, technological, and regulatory innovations offer hope for new treatments.
  • Ensuring scientific progress translates into available, effective medicines is crucial.

Purpose of the Study:

  • To present a vision for accelerating the development of safe and effective medicines.
  • To highlight the importance of collaboration among regulators, academia, industry, patients, and healthcare professionals.
  • To outline strategies for future-proofing the regulatory ecosystem.

Main Methods:

  • The European Medicines Agency (EMA) collaborates with stakeholders.
  • Strategic initiatives and concrete examples illustrate the process.
  • Focus on continuous evolution of regulatory science and patient-centered evidence generation.

Main Results:

  • The EMA supports regulatory science evolution.
  • Patient-focused refinements in evidence generation and medicines assessments are facilitated.
  • Forward-looking initiatives monitor and examine innovative developments.

Conclusions:

  • Continued transparent collaboration is key to accelerating medicine availability.
  • Future-proofing the regulatory ecosystem ensures scientific progress leads to better health outcomes.
  • The vision aims to translate innovation into meaningful health benefits for patients.